PT3312177T - Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo - Google Patents

Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo

Info

Publication number
PT3312177T
PT3312177T PT168077410T PT16807741T PT3312177T PT 3312177 T PT3312177 T PT 3312177T PT 168077410 T PT168077410 T PT 168077410T PT 16807741 T PT16807741 T PT 16807741T PT 3312177 T PT3312177 T PT 3312177T
Authority
PT
Portugal
Prior art keywords
same
pharmaceutical composition
derivative compound
tricyclic derivative
preparing
Prior art date
Application number
PT168077410T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Onconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc filed Critical Onconic Therapeutics Inc
Publication of PT3312177T publication Critical patent/PT3312177T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT168077410T 2015-06-09 2016-06-03 Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo PT3312177T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150081021 2015-06-09

Publications (1)

Publication Number Publication Date
PT3312177T true PT3312177T (pt) 2021-05-17

Family

ID=57503424

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168077410T PT3312177T (pt) 2015-06-09 2016-06-03 Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo

Country Status (21)

Country Link
US (1) US10464919B2 (https=)
EP (1) EP3312177B1 (https=)
JP (2) JP2018521033A (https=)
KR (1) KR101837047B1 (https=)
CN (1) CN107849040B (https=)
AU (1) AU2016276806B9 (https=)
BR (1) BR112017026392B1 (https=)
CA (1) CA2990277C (https=)
CL (1) CL2017003138A1 (https=)
DK (1) DK3312177T3 (https=)
ES (1) ES2870203T3 (https=)
MX (1) MX375707B (https=)
MY (1) MY194590A (https=)
NZ (1) NZ738187A (https=)
PH (1) PH12017502228B1 (https=)
PL (1) PL3312177T3 (https=)
PT (1) PT3312177T (https=)
RU (1) RU2715413C2 (https=)
SA (1) SA517390509B1 (https=)
WO (1) WO2016200101A2 (https=)
ZA (1) ZA201708663B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180252A1 (es) 2015-06-09 2018-02-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
EP3953360B1 (en) * 2019-04-09 2024-02-28 F. Hoffmann-La Roche AG Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)
SI3999506T1 (sl) 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1
MX2022001200A (es) * 2019-07-29 2022-02-21 Jeil Pharmaceutical Co Ltd Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.
US20220324899A1 (en) * 2019-08-14 2022-10-13 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
AU2020372682A1 (en) * 2019-10-31 2022-06-09 Jd Bioscience Inc. Tricyclic compound and pharmaceutical use thereof
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
EP4328224A4 (en) * 2021-04-22 2025-06-18 Wigen Biomedicine Technology (Shanghai) Co., Ltd. PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
EP4342470A4 (en) * 2021-05-18 2025-04-30 Onconic Therapeutics Inc. THERAPEUTIC AGENT FOR PARP INHIBITOR-RESISTANT CANCER
MX2023013624A (es) * 2021-05-18 2023-11-30 Onconic Therapeutics Inc Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma.
MA63136A1 (fr) * 2021-05-18 2024-06-28 Onconic Therapeutics Inc. Agent thérapeutique contre le cancer résistant à un inhibiteur de parp
WO2023011608A1 (zh) * 2021-08-05 2023-02-09 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
CN118119618A (zh) * 2021-09-09 2024-05-31 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
KR102867210B1 (ko) 2021-10-01 2025-10-14 신테라, 인크. 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
US20250163022A1 (en) * 2021-12-22 2025-05-22 Synnovation Therapeutics, Inc. Parp1 inhibitors
KR20240134366A (ko) * 2022-01-13 2024-09-09 에이스랜드 테라퓨틱스 (홍콩) 리미티드 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CN119013279A (zh) * 2022-03-11 2024-11-22 上海瑛派药业有限公司 作为parp抑制剂的取代的三环类化合物及其应用
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
AU2023259236B2 (en) 2022-04-28 2025-01-09 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
JP7835895B2 (ja) * 2022-05-07 2026-03-25 サイブランチ セラピューティクス カンパニー リミテッド Parp1を選択的に阻害するフルオロキノキサリノン誘導体
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024099416A1 (zh) * 2022-11-10 2024-05-16 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途
WO2024255697A1 (zh) * 2023-06-13 2024-12-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
KR101179753B1 (ko) * 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
AU2009314760B2 (en) * 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법

Also Published As

Publication number Publication date
CN107849040B (zh) 2021-04-06
ZA201708663B (en) 2019-04-24
JP2018521033A (ja) 2018-08-02
MX2017016013A (es) 2018-04-20
JP2019163287A (ja) 2019-09-26
ES2870203T3 (es) 2021-10-26
SA517390509B1 (ar) 2021-06-02
DK3312177T3 (da) 2021-07-05
BR112017026392B1 (pt) 2023-12-26
PH12017502228B1 (en) 2022-08-03
BR112017026392A2 (https=) 2018-08-21
RU2017146130A (ru) 2019-07-16
CA2990277A1 (en) 2016-12-15
KR20160144916A (ko) 2016-12-19
EP3312177B1 (en) 2021-04-14
EP3312177A4 (en) 2018-12-05
AU2016276806A1 (en) 2018-01-04
CL2017003138A1 (es) 2018-06-15
NZ738187A (en) 2019-03-29
RU2715413C2 (ru) 2020-02-28
MY194590A (en) 2022-12-05
MX375707B (es) 2025-03-06
WO2016200101A3 (ko) 2017-02-02
PL3312177T3 (pl) 2021-11-02
US20180162834A1 (en) 2018-06-14
JP6806969B2 (ja) 2021-01-06
CN107849040A (zh) 2018-03-27
AU2016276806B2 (en) 2019-02-14
CA2990277C (en) 2021-10-26
RU2017146130A3 (https=) 2019-07-17
US10464919B2 (en) 2019-11-05
EP3312177A2 (en) 2018-04-25
KR101837047B1 (ko) 2018-03-09
PH12017502228A1 (en) 2018-06-11
AU2016276806B9 (en) 2019-02-21
WO2016200101A2 (ko) 2016-12-15

Similar Documents

Publication Publication Date Title
ZA201708663B (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
PT3453707T (pt) Derivado de benzazepina, método de preparação, composição farmacêutica e a sua utilização
PT3214081T (pt) Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
SI3313817T1 (sl) Biciklični derivati, postopek njihove priprave in farmacevtski sestavki, ki jih vsebujejo
PT3339294T (pt) Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl
EP3153165A4 (en) Rapamycin derivative, preparation method therefor, and pharmaceutical composition and uses thereof
IL256686A (en) Preparation method for lyophilized pharmaceutical preparations and pharmaceutical preparations prepared in this way
EP3199541A4 (en) Cyclic peptide derivative, method for preparing same and composition thereof
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
PL3391893T3 (pl) Kompozycja farmaceutyczna do leczenia białaczki i sposób jej przygotowania
IL251456A0 (en) Substances with agonist activity for gpr119, processes for their preparation and preparations containing them
HUE047537T2 (hu) Új heterociklusos vegyület, eljárás annak elõállítására, és az azt tartalmazó gyógyászati készítmény
IL267914B (en) History of monoterpene phenol, process for their preparation and pharmaceutical preparations containing them
ZA201908090B (en) Pharmaceutical composition and method for preparing same
HUE059610T2 (hu) Gyógyszerészeti készítmény, amely indolszármazékokat tartalmaz, valamint eljárás annak elõállítására és felhasználására
ZA201804391B (en) Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same
EP3138830A4 (en) Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same
TWI562978B (en) Method for preparation of 1,4-cyclohexanedialkanol
PL3061765T3 (pl) Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek